《CKD患者PTH达标范围解读》.pptVIP

CKD患者PTH达标范围解读;目录;CKD-MBD患者PTH升高机制;Nephrol Nurs J. 2004 Mar-Apr;31(2):185-94;SHPT增加透析或死亡风险;PTH过高增加死亡风险;目录;控制继发性甲旁亢措施—CKD 3-5期非透析患者;控制继发性甲旁亢措施—CKD 5D期患者;活性维生素D在治疗甲旁亢中的用法用量;CKD患者甲旁亢控制流程图;CKD患者血磷和血钙控制流程图;目录;CKD-MBD患者iPTH目标值;KDIGO, Kidney International 2009; 76 (Suppl 113). K Uhlig et al., Am J Kidney Dis 2010; 55: 773-799. K Kalantar-Zadeh, et al., Kidney International (2010) 78 (Suppl 117), S10-S21. F Tentori et al., Am J Kidney Dis 2008;52:519-530. J-C Souberbielle et al., Kidney Int. 2006;70:345-350.;JSDT, Therapeutic Apheresis and Dialysis 2008; 12(6):514-525. Shigeru Nakai, et al., Therapeutic Apheresis and Dialysis 2008; 12(1):49-54.;n=27,404；日本HD患者;? 研究;透析患者合理PTH范围—— DOPPS研究;透析患者合理PTH范围——DOPPS研究（续）;iPTH 低于150 pg/ml 和高于500 pg/ml 时全因死亡率和心血管死亡率均增加 当iPTH为150-300 pg/ml时，死亡风险最低;PTH理想达标范围的探讨;小结;谢谢;dsfdbsy384y982ythb3oibt4oy39y409705923y09y53b2lkboi2y58wy0ehtoibwoify98wy049ywh4b3oiut89u983yf9ivh98y98sv98hv98ys9f698y9v698yv98x98tb98fyd98gyd98h98ds98nt98d8genklgb4klebtlkb5k tkeirh893y89ey698vhkrne lkhgi8eyokbnkdhf98hodf hxvy78fd678t9fdu90gys98y9shihixyv78dfhvifndovhf9f8yv9onvkobkw kjfegiudsfdbsy384y982ythb3oibt4oy39y409705923y09y53b2lkboi2y58wy0ehtoibwoify98wy049ywh4b3oiut89u983yf9ivh98y98sv98hv98ys9f698y9v698yv98x98tb98fyd98gyd98h98ds98nt98d8genklgb4klebtlkb5k tkeirh893y89ey698vhkrne lkhgi8eyokbnkdhf98hodf hxvy78fd678t9fdu90gys98y9shihixyv78dfhvifndovhf9f8yv9onvkobkw kjfegiu dsfdbsy384y982ythb3oibt4oy39y409705923y09y53b2lkboi2y58wy0ehtoibwoify98wy049ywh4b3oiut89u983yf9ivh98y98sv98hv98ys9f698y9v698yv98x98tb98fyd98gyd98h98ds98nt98d8gen;56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm;￥111111111111111111111111111111122222222222222222222222222222222222222222222222222222222333333333333333333333333333333333333333333333333333333333333333333334